Junichi Soh

List of Publications by Year
in descending order

187 papers	5,889 citations	81900 39 h-index	88630 70 g-index
189 all docs	189 docs citations	189 times ranked	8516 citing authors

#	Article	IF	Citations
1	Presence of a Ground-glass Opacity Component is the True Prognostic Determinant in Clinical Stage I Non-Small Cell Lung Cancer. JTO Clinical and Research Reports, 2022, 3, 100321.	1.1	1
2	Limited resection for stage IA radiologically invasive lung cancer: a real-world nationwide database study. European Journal of Cardio-thoracic Surgery, 2022, 62, .	1.4	14
3	The neutrophil-to-lymphocyte ratio as a novel independent prognostic factor for multiple metastatic lung tumors from various sarcomas. Surgery Today, 2021, 51, 127-135.	1.5	10
4	Inter- and Intratumor Heterogeneity of EGFR Compound Mutations in Nonâ€“Small Cell Lung Cancers: Analysis of Five Cases. Clinical Lung Cancer, 2021, 22, e141-e145.	2.6	5
5	Effectiveness of scheduled intravenous acetaminophen in the postoperative pain management of video-assisted thoracic surgery. Surgery Today, 2021, 51, 589-594.	1.5	3
6	Salvage surgery after definitive chemoradiotherapy for patients with non-small cell lung cancer. Translational Lung Cancer Research, 2021, 10, 555-562.	2.8	16
7	The prevalence and risk factors associated with preoperative deep venous thrombosis in lung cancer surgery. Surgery Today, 2021, 51, 1480-1487.	1.5	5
8	The prognostic nutritional index is correlated negatively with the lung allocation score and predicts survival after both cadaveric and living-donor lobar lung transplantation. Surgery Today, 2021, 51, 1610-1618.	1.5	9
9	Activity of <scp>tarloxotinibâ€£</scp> in cells with <scp>EGFR</scp> exonâ€20 insertion mutations and mechanisms of acquired resistance. Thoracic Cancer, 2021, 12, 1511-1516.	1.9	15
10	Phase II Study of Neoadjuvant Concurrent Chemo-immuno-radiation Therapy Followed by Surgery and Adjuvant Immunotherapy for Resectable Stage IIIA-B (Discrete N2) Nonâ€“small-cell Lung Cancer: SQUAT trial (WJOG 12119L). Clinical Lung Cancer, 2021, 22, 596-600.	2.6	14
11	Dose-dependence in acquisition of drug tolerant phenotype and high RYK expression as a mechanism of osimertinib tolerance in lung cancer. Lung Cancer, 2021, 154, 84-91.	2.0	9
12	Randomized phase II study of daily and alternate-day administration of S-1 for adjuvant chemotherapy in completely-resected stage I non-small cell lung cancer: results of the Setouchi Lung Cancer Group Study 1301. BMC Cancer, 2021, 21, 506.	2.6	3
13	KRAS Secondary Mutations That Confer Acquired Resistance to KRAS G12C Inhibitors, Sotorasib and Adagrasib, and Overcoming Strategies: Insights From InÂVitro Experiments. Journal of Thoracic Oncology, 2021, 16, 1321-1332.	1.1	118
14	Perioperative Therapy for Non-Small Cell Lung Cancer with Immune Checkpoint Inhibitors. Cancers, 2021, 13, 4035.	3.7	18
15	Activity and mechanism of acquired resistance to tarloxotinib in HER2 mutant lung cancer: an in vitro study. Translational Lung Cancer Research, 2021, 10, 3659-3670.	2.8	7
16	Intra-tumor and inter-tumor heterogeneity in MET exon 14 skipping mutations and co-mutations in pulmonary pleomorphic carcinomas. Clinical Lung Cancer, 2021, , .	2.6	0
17	Adjuvant therapy of operable nonsmall cell lung cancer: an update. Current Opinion in Oncology, 2021, 33, 47-54.	2.4	13
18	A Simple Prognostic Benefit Scoring System for Sarcoma Patients with Pulmonary Metastases: Sarcoma Lung Metastasis Score. Annals of Surgical Oncology, 2021, 28, 3884-3890.	1.5	6

#	Article	IF	Citations
19	Frequent EGFR mutations and better prognosis in positron emission tomography-negative, solid-type lung cancer. Clinical Lung Cancer, 2021, , .	2.6	3
20	In vitro validation study of HER2 and HER4 mutations identified in an ad hoc secondary analysis of the LUX-Lung 8 randomized clinical trial. Lung Cancer, 2021, 162, 79-85.	2.0	1
21	Successful Bronchoscopic Treatment for Postoperative Bronchopleural Fistula Using N-butyl-2-cyanoacrylate (NBCA): Report of a Post-completion Pneumonectomy Case with a History of Induction Chemoradiotherapy Followed by Bilobectomy for Advanced Lung Cancer. Acta Medica Okayama, 2021, 75, 91-94.	0.2	0
22	Pulmonary Enteric Adenocarcinoma Harboring a BRAF G469V Mutation.. Acta Medica Okayama, 2021, 75, 759-762.	0.2	1
23	Pulmonary resection in a prone position for lung cancer invading the spine. General Thoracic and Cardiovascular Surgery, 2020, 68, 298-301.	0.9	1
24	Continuing surgical education of non-technical skills. Annals of Medicine and Surgery, 2020, 58, 177-186.	1.1	4
25	Spatial heterogeneity of acquired resistance mechanisms to 1st/2nd generation EGFR tyrosine kinase inhibitors in lung cancer. Lung Cancer, 2020, 148, 100-104.	2.0	6
26	Fibrosis or Necrosis in Resected Lymph Node Indicate Metastasis Before Chemoradiotherapy in Lung Cancer Patients. Anticancer Research, 2020, 40, 4419-4423.	1.1	5
27	Chronic Lung Injury After Trimodality Therapy for Locally Advanced Non-Small Cell Lung Cancer. Annals of Thoracic Surgery, 2020, 112, 279-288.	1.3	4
28	Prognostic nutrition index affects the prognosis of patients undergoing trimodality therapy for locally advanced non-small cell lung cancer. Surgery Today, 2020, 50, 1610-1618.	1.5	7
29	Antitumor Effects of Pan-RAF Inhibitor LY3009120 Against Lung Cancer Cells Harboring Oncogenic BRAF Mutation. Anticancer Research, 2020, 40, 2667-2673.	1.1	6
30	Prognostic value of plasma fibrinogen and d-dimer levels in patients with surgically resected non-small cell lung cancer. Surgery Today, 2020, 50, 1427-1433.	1.5	11
31	DV200 Index for Assessing RNA Integrity in Next-Generation Sequencing. BioMed Research International, 2020, 2020, 1-6.	1.9	38
32	Survival Outcomes of Treatment with Radiofrequency Ablation, Stereotactic Body Radiotherapy, or Sublobar Resection for Patients with Clinical Stage I Nonâ€“Small-Cell Lung Cancer: A Single-Center Evaluation. Journal of Vascular and Interventional Radiology, 2020, 31, 1044-1051.	0.5	16
33	Pulmonary aspergillosis as a late complication after surgery for locally advanced non-small cell lung cancer treated with induction chemoradiotherapy. Surgery Today, 2020, 50, 863-871.	1.5	6
34	YES1 activation induces acquired resistance to neratinib in HER2â€amplified breast and lung cancers. Cancer Science, 2020, 111, 849-856.	3.9	15
35	Chemoradiation therapy for non-small cell lung cancer exacerbates thoracic aortic calcification determined by computed tomography. Heart and Vessels, 2020, 35, 1401-1408.	1.2	3
36	Surgical therapy for pulmonary metastasis of breast cancer. Translational Cancer Research, 2020, 9, 5044-5052.	1.0	5

#	Article	IF	Citations
37	Prognostic implications of preoperative versus postoperative circulating tumor DNA in surgically resected lung cancer patients: a pilot study. Translational Lung Cancer Research, 2020, 9, 1915-1923.	2.8	34
38	Perioperative Treatment for the Eradication of Non-small Cell Lung Cancer. Japanese Journal of Lung Cancer, 2020, 60, 891-894.	0.1	0
39	Association between Histological Types and Enhancement of Dynamic CT for Primary Lung Cancer. Acta Medica Okayama, 2020, 74, 129-135.	0.2	1
40	A Giant Thymic Cyst Accompanied by Acute Mediastinitis. Acta Medica Okayama, 2020, 74, 431-433.	0.2	0
41	Impact of pathological stage and histological subtype on clinical outcome of adjuvant chemotherapy of paclitaxel plus carboplatin versus oral uracilâ€“tegafur for non-small cell lung cancer: subanalysis of SLCG0401 trial. International Journal of Clinical Oncology, 2019, 24, 1367-1376.	2.2	4
42	Long-term spontaneous remission with active surveillance in IgG4-related pleuritis: A case report and literature review. Respiratory Medicine Case Reports, 2019, 28, 100938.	0.4	9
43	Comparison of PD-L1 Expression Status between Pure-Solid Versus Part-Solid Lung Adenocarcinomas. Biomolecules, 2019, 9, 456.	4.0	11
44	Acquired resistance mechanisms to afatinib in <scp>HER</scp>2â€amplified gastric cancer cells. Cancer Science, 2019, 110, 2549-2557.	3.9	26
45	Droplet digital PCR as a novel system for the detection of microRNAâ€'34b/c methylation in circulating DNA in malignant pleural mesothelioma. International Journal of Oncology, 2019, 54, 2139-2148.	3.3	14
46	Critical role of the MCAM-ETV4 axis triggered by extracellular S100A8/A9 in breast cancer aggressiveness. Neoplasia, 2019, 21, 627-640.	5.3	36
47	Melanoma cell adhesion molecule is the driving force behind the dissemination of melanoma upon S100A8/A9 binding in the original skin lesion. Cancer Letters, 2019, 452, 178-190.	7.2	32
48	Application of amplicon-based targeted sequencing with the molecular barcoding system to detect uncommon minor EGFR mutations in patients with treatment-naÃ¯ve lung adenocarcinoma. BMC Cancer, 2019, 19, 175.	2.6	1
49	Ganetespib in Epidermal Growth Factor Receptor-Tyrosine Kinase Inhibitor-resistant Non-small Cell Lung Cancer. Anticancer Research, 2019, 39, 1767-1775.	1.1	10
50	Neuroplastinâ€Î²2 mediates S100A8/A9â€induced lung cancer disseminative progression. Molecular Carcinogenesis, 2019, 58, 980-995.	2.7	28
51	Clinical outcome of patients with recurrent non-small cell lung cancer after trimodality therapy. Surgery Today, 2019, 49, 601-609.	1.5	8
52	Antiâ€'tumor effect of neratinib against lung cancer cells harboring HER2 oncogene alterations. Oncology Letters, 2019, 17, 2729-2736.	1.8	15
53	Dose-volume parameters predict radiation pneumonitis after induction chemoradiotherapy followed by surgery for non-small cell lung cancer: a retrospective analysis. BMC Cancer, 2019, 19, 1144.	2.6	12
54	Long-term outcomes of pneumonectomy, back-table lung preservation, double-sleeve resection and reimplantation for advanced central lung cancer: the Oto procedure. European Journal of Cardio-thoracic Surgery, 2019, 56, 213-214.	1.4	3

#	Article	IF	Citations
55	Newly developed antiâ€S100A8/A9 monoclonal antibody efficiently prevents lung tropic cancer metastasis. International Journal of Cancer, 2019, 145, 569-575.	5.1	35
56	Activation of AXL as a Preclinical Acquired Resistance Mechanism Against Osimertinib Treatment inEGFR-Mutant Nonâ€“Small Cell Lung Cancer Cells. Molecular Cancer Research, 2019, 17, 499-507.	3.4	65
57	exSSSRs (extracellular S100 soil sensor receptors)â€Fc fusion proteins work as prominent decoys to S100A8/A9â€induced lung tropic cancer metastasis. International Journal of Cancer, 2019, 144, 3138-3145.	5.1	20
58	Antitumor activity of panâ€HER inhibitors in HER 2â€positive gastric cancer. Cancer Science, 2018, 109, 1166-1176.	3.9	29
59	Second primary cancer in survivors of locally advanced non-small cell lung cancer treated with concurrent chemoradiation followed by surgery. Japanese Journal of Clinical Oncology, 2018, 48, 287-290.	1.3	3
60	Therapeutic potential of targeting S100A11 in malignant pleural mesothelioma. Oncogenesis, 2018, 7, 11.	4.9	13
61	Therapeutic strategies for afatinibâ€resistant lung cancer harboring <scp>HER</scp>2 alterations. Cancer Science, 2018, 109, 1493-1502.	3.9	23
62	A Multicenter Randomized Controlled Study ofÂPaclitaxel plus Carboplatin versus Oral Uracil-Tegafur as the Adjuvant Chemotherapy inÂResected Nonâ€“Small Cell Lung Cancer. Journal of Thoracic Oncology, 2018, 13, 699-706.	1.1	24
63	Tumor-suppressive effect of LRIG1, a negative regulator of ErbB, in non-small cell lung cancer harboring mutant EGFR. Carcinogenesis, 2018, 39, 719-727.	2.8	22
64	Is Surgery after Chemoradiotherapy Feasible in Lung Cancer Patients with Superior Vena Cava Invasion?. Annals of Thoracic and Cardiovascular Surgery, 2018, 24, 131-138.	0.8	2
65	Comparative mutational evaluation of multiple lung cancers by multiplex oncogene mutation analysis. Cancer Science, 2018, 109, 3634-3642.	3.9	23
66	Combined inhibition of MEK and PI3K pathways overcomes acquired resistance to EGFRâ€TKIs in nonâ€small cell lung cancer. Cancer Science, 2018, 109, 3183-3196.	3.9	46
67	Myoepithelioma occurring in the posterior mediastinum harboring EWSR1 rearrangement: a case report. Japanese Journal of Clinical Oncology, 2018, 48, 851-854.	1.3	3
68	Dose-Volume Parameters Predict Radiation Pneumonitis after Surgery with Induction Concurrent Chemoradiotherapy for Non-small Cell Lung Cancer. Acta Medica Okayama, 2018, 72, 507-513.	0.2	6
69	Targeting the miR-200c/LIN28B axis in acquired EGFR-TKI resistance non-small cell lung cancer cells harboring EMT features. Scientific Reports, 2017, 7, 40847.	3.3	54
70	Optimal method for quantitative detection of plasma EGFR T790M mutation using droplet digital PCR system. Oncology Reports, 2017, 37, 3100-3106.	2.6	12
71	Advantage of Induction Chemoradiotherapy for Lung Cancer in Securing Cancer-Free Bronchial Margin. Annals of Thoracic Surgery, 2017, 104, 971-978.	1.3	5
72	P2.02-035 The Advantage of Induction Chemoradiotherapy in Bronchoplastic Procedure for Non-Small Cell Lung Cancer Accompanied with Central Disease Region. Journal of Thoracic Oncology, 2017, 12, S868-S869.	1.1	0

#	Article	IF	Citations
73	P2.02-054 Impact of Prognostic Nutrition Index for Induction Chemoradiotherapy Followed by Surgery in Locally Advanced Non-Small Lung Cancers. Journal of Thoracic Oncology, 2017, 12, S880-S881.	1.1	0
74	Feasibility of adjuvant chemotherapy with S-1 plus carboplatin followed by single-agent maintenance therapy with S-1 for completely resected non-small-cell lung cancer: results of the Setouchi Lung Cancer Group Study 1001. International Journal of Clinical Oncology, 2017, 22, 274-282.	2.2	11
75	Elacridar, a third-generation ABCB1 inhibitor, overcomes resistance to docetaxel in non-small cell lung cancer. Oncology Letters, 2017, 14, 4349-4354.	1.8	15
76	Effects of Cold Ischemia on RNA Stability and Quality of Lung Tissues Based on Standard PREanalytical Code Categorization. Biopreservation and Biobanking, 2017, 15, 484-486.	1.0	0
77	Estimation of age-related DNA degradation from formalin-fixed and paraffin-embedded tissue according to the extraction methods. Experimental and Therapeutic Medicine, 2017, 14, 2683-2688.	1.8	58
78	Radiofrequency ablation of pulmonary metastases from sarcoma: single-center retrospective evaluation of 46 patients. Japanese Journal of Radiology, 2017, 35, 61-67.	2.4	17
79	Early postoperative complications after middle lobe-preserving surgery for secondary lung cancer. Surgery Today, 2017, 47, 601-605.	1.5	6
80	Yes1 signaling mediates the resistance to Trastuzumab/Lap atinib in breast cancer. PLoS ONE, 2017, 12, e0171356.	2.5	33
81	Induction chemoradiotherapy using docetaxel and cisplatin with definitive-dose radiation followed by surgery for locally advanced non-small cell lung cancer. Journal of Thoracic Disease, 2017, 9, 3076-3086.	1.4	4
82	Is tumor location an independent prognostic factor in locally advanced non-small cell lung cancer treated with trimodality therapy?. Journal of Thoracic Disease, 2017, 9, E489-E491.	1.4	3
83	Diagnostic Value of Dual-time-point F-18 FDG PET/CT and Chest CT for the Prediction of Thymic Epithelial Neoplasms. Acta Medica Okayama, 2017, 71, 105-112.	0.2	6
84	Restrictive ventilatory impairment is associated with poor outcome in patients with cT1aN0M0 peripheral squamous cell carcinoma of the lung. Journal of Thoracic Disease, 2017, 9, 4325-4335.	1.4	5
85	Distant Bystander Effect of REIC/DKK3 Gene Therapy Through Immune System Stimulation in Thoracic Malignancies. Anticancer Research, 2017, 37, 301-308.	1.1	10
86	Interaction of cytokeratin 19 head domain and HER2 in the cytoplasm leads to activation of HER2-Erk pathway. Scientific Reports, 2016, 6, 39557.	3.3	22
87	Randomized feasibility study of S-1 for adjuvant chemotherapy in completely resected Stage IA nonâ€“small-cell lung cancer: results of the Setouchi Lung Cancer Group Study 0701. Japanese Journal of Clinical Oncology, 2016, 46, 741-747.	1.3	8
88	Establishment and molecular characterization of cell lines from Japanese patients with malignant pleural mesothelioma. Oncology Letters, 2016, 11, 705-712.	1.8	3
89	Antitumor effect of afatinib, as a human epidermal growth factor receptor 2â€targeted therapy, in lung cancers harboring HER 2 oncogene alterations. Cancer Science, 2016, 107, 45-52.	3.9	71
90	Active Secretion of Dimerized S100A11 Induced by the Peroxisome in Mesothelioma Cells. Cancer Microenvironment, 2016, 9, 93-105.	3.1	14

#	Article	IF	Citations
91	The Feasibility of Median Sternotomy With or Without Thoracotomy for Locally Advanced Non-Small Cell Lung Cancer Treated With Induction Chemoradiotherapy. Annals of Thoracic Surgery, 2016, 102, 985-992.	1.3	7
92	Genetic alterations in lung adenocarcinoma with a micropapillary component. Molecular and Clinical Oncology, 2016, 4, 195-200.	1.0	6
93	The proliferative effects of asbestos-exposed peripheral blood mononuclear cells on mesothelial cells. Oncology Letters, 2016, 11, 3308-3316.	1.8	7
94	Radiofrequency Ablation of Lung Tumors Using a Multitined Expandable Electrode: Impact of the Electrode Array Diameter on Local Tumor Progression. Journal of Vascular and Interventional Radiology, 2016, 27, 87-95.	0.5	23
95	Induction S-1+Concurrent Radiotherapy Followed by Surgical Resection of Locally Advanced Non-small-cell Lung Cancer in an Elderly Patient. Acta Medica Okayama, 2016, 70, 63-5.	0.2	1
96	Study about the Efficacy of Metformin to Immune Function in Cancer Patients. Acta Medica Okayama, 2016, 70, 327-30.	0.2	2
97	Usefulness of Thoracoscopic Debridement for Chronic Empyema after an Extrapleural Pneumonectomy. Acta Medica Okayama, 2016, 70, 507-510.	0.2	1
98	Ethnicity affects EGFR and KRAS gene alterations of lung adenocarcinoma. Oncology Letters, 2015, 10, 1775-1782.	1.8	27
99	Primary pulmonary melanoma: a report of two cases. World Journal of Surgical Oncology, 2015, 13, 274.	1.9	9
100	Lower lobe origin is a poor prognostic factor in locally advanced non-small-cell lung cancer patients treated with induction chemoradiotherapy. Molecular and Clinical Oncology, 2015, 3, 706-712.	1.0	18
101	DNA copy number gains in malignant pleural mesothelioma. Oncology Letters, 2015, 10, 3274-3278.	1.8	3
102	TAE226, a Bis-Anilino Pyrimidine Compound, Inhibits the EGFR-Mutant Kinase Including T790M Mutant to Show Anti-Tumor Effect on EGFR-Mutant Non-Small Cell Lung Cancer Cells. PLoS ONE, 2015, 10, e0129838.	2.5	9
103	Acquisition of cancer stem cellâ€like properties in nonâ€small cell lung cancer with acquired resistance to afatinib. Cancer Science, 2015, 106, 1377-1384.	3.9	62
104	Clinicopathological characteristics and lymph node metastasis pathway of non-small-cell lung cancer located in the left lingular division. Interactive Cardiovascular and Thoracic Surgery, 2015, 20, 791-796.	1.1	13
105	Fever after lung radiofrequency ablation: Prospective evaluation of its incidence and associated factors. European Journal of Radiology, 2015, 84, 2202-2209.	2.6	5
106	Hsp90 inhibitor NVP-AUY922 enhances the radiation sensitivity of lung cancer cell lines with acquired resistance to EGFR-tyrosine kinase inhibitors. Oncology Reports, 2015, 33, 1499-1504.	2.6	17
107	Extended sleeve lobectomy after induction chemoradiotherapy for non-small cell lung cancer. Surgery Today, 2015, 45, 1121-1126.	1.5	15
108	Predicting pleural invasion using HRCT and 18F-FDG PET/CT in lung adenocarcinoma with pleural contact. Annals of Nuclear Medicine, 2015, 29, 757-765.	2.2	22

#	Article	IF	Citations
109	Percutaneous Radiofrequency Ablation of Lung Cancer Presenting as Ground-Glass Opacity. CardioVascular and Interventional Radiology, 2015, 38, 409-415.	2.0	37
110	Adult Mesenchymal Hamartoma of the Chest Wall: Report of a Case. Annals of Thoracic and Cardiovascular Surgery, 2014, 20, 663-665.	0.8	3
111	Density of Tumor-Infiltrating FOXP3+ T Cells as a Response Marker for Induction Chemoradiotherapy and a Potential Prognostic Factor in Patients Treated with Trimodality Therapy for Locally Advanced Non-Small Cell Lung Cancer. Annals of Thoracic and Cardiovascular Surgery, 2014, 20, 980-986.	0.8	9
112	Novel Germline Mutation in the Transmembrane Domain of HER2 in Familial Lung Adenocarcinomas. Journal of the National Cancer Institute, 2014, 106, djt338.	6.3	99
113	Hereditary Lung Cancer Syndrome Targets Never Smokers with Germline EGFR Gene T790M Mutations. Journal of Thoracic Oncology, 2014, 9, 456-463.	1.1	112
114	Use of a vessel sealing system versus conventional electrocautery for lung parenchymal resection: a comparison of the clinicopathological outcomes in porcine lungs. Surgery Today, 2014, 44, 540-545.	1.5	8
115	Validity of using lobe-specific regional lymph node stations to assist navigation during lymph node dissection in early stage non-small cell lung cancer patients. Surgery Today, 2014, 44, 2028-2036.	1.5	11
116	Massive Subcutaneous and Mediastinal Emphysema with Little Pneumothorax Treated by Surgery after Pulmonary Radiofrequency Ablation. CardioVascular and Interventional Radiology, 2014, 37, 548-551.	2.0	3
117	A Case of Carcinoma Showing Thymus-Like Differentiation with a Rapidly Lethal Course. Case Reports in Oncology, 2014, 7, 840-844.	0.7	3
118	Presence of the minor EGFR T790M mutation is associated with drug-sensitive EGFR mutations in lung adenocarcinoma patients. Oncology Reports, 2014, 32, 145-152.	2.6	18
119	Anti-Cancer Effects of REIC/Dkk-3-encoding Adenoviral Vector for the Treatment of Non-small Cell Lung Cancer. PLoS ONE, 2014, 9, e87900.	2.5	23
120	Preclinical evaluation of microRNA-34b/c delivery for malignant pleural mesothelioma. Acta Medica Okayama, 2014, 68, 23-6.	0.2	16
121	Drug resistance to EGFR tyrosine kinase inhibitors for non-small cell lung cancer. Acta Medica Okayama, 2014, 68, 191-200.	0.2	15
122	Oncogenic KRAS-induced epiregulin overexpression contributes to aggressive phenotype and is a promising therapeutic target in non-small-cell lung cancer. Oncogene, 2013, 32, 4034-4042.	5.9	59
123	The degree of microRNA-34b/c methylation in serum-circulating DNA is associated with malignant pleural mesothelioma. Lung Cancer, 2013, 82, 485-490.	2.0	43
124	Contralateral pneumothorax in bullous lung after pneumonectomy: report of two cases. General Thoracic and Cardiovascular Surgery, 2013, 61, 35-37.	0.9	5
125	Bronchoplasty to adjust mismatches in the proximal and distal bronchial stumps during bronchial sleeve resection of the left lower lobe and lingular division. European Journal of Cardio-thoracic Surgery, 2013, 43, 182-183.	1.4	8
126	Sacrificing the pulmonary arterial branch to the spared lobe is a risk factor of bronchopleural fistula in sleeve lobectomy after chemoradiotherapy. European Journal of Cardio-thoracic Surgery, 2013, 43, 568-572.	1.4	13

#	Article	IF	Citations
127	Acquired Resistance to EGFR Inhibitors Is Associated with a Manifestation of Stem Cellâ€“like Properties in Cancer Cells. Cancer Research, 2013, 73, 3051-3061.	0.9	241
128	CDKN2A/p16 Inactivation Mechanisms and Their Relationship to Smoke Exposure and Molecular Features in Nonâ€“Small-Cell Lung Cancer. Journal of Thoracic Oncology, 2013, 8, 1378-1388.	1.1	71
129	Impact of aberrant methylation of microRNA-9 family members on non-small cell lung cancers. Molecular and Clinical Oncology, 2013, 1, 185-189.	1.0	22
130	Downregulation of microRNA-34 induces cell proliferation and invasion of human mesothelial cells. Oncology Reports, 2013, 29, 2169-2174.	2.6	46
131	Impact of GLUT1 and Ki-67 expression on early-stage lung adenocarcinoma diagnosed according to a new international multidisciplinary classification. Oncology Reports, 2013, 29, 133-140.	2.6	33
132	Silenced expression of NFKBIA in lung adenocarcinoma patients with a never-smoking history. Acta Medica Okayama, 2013, 67, 19-24.	0.2	9
133	A Case of Delayed Massive Hemothorax Caused by the Rupture of a Pulmonary Artery Pseudoaneurysm after Radiofrequency Ablation of Lung Tumors. Japanese Journal of Clinical Oncology, 2012, 42, 646-649.	1.3	13
134	Intrathoracic irrigation with arbekacin for methicillin-resistant Staphylococcus aureus empyema following lung resection. Interactive Cardiovascular and Thoracic Surgery, 2012, 15, 437-441.	1.1	7
135	Presence of EGFR mutation in pathologically non-malignant specimens from computed tomography-guided lung needle biopsies. Oncology Letters, 2012, 3, 401-404.	1.8	2
136	Impact of age on epidermal growth factor receptor mutation in lung cancer. Lung Cancer, 2012, 78, 207-211.	2.0	35
137	Induction Chemoradiotherapy Followed by Surgical Resection for Clinical T3 or T4 Locally Advanced Nonâ€“Small Cell Lung Cancer. Annals of Surgical Oncology, 2012, 19, 2685-2692.	1.5	23
138	Knockdown of the Epidermal Growth Factor Receptor Gene to Investigate Its Therapeutic Potential for the Treatment of Nonâ€“Small-Cell Lung Cancers. Clinical Lung Cancer, 2012, 13, 488-493.	2.6	12
139	The anti-proliferative effect of heat shock protein 90 inhibitor, 17-DMAG, on non-small-cell lung cancers being resistant to EGFR tyrosine kinase inhibitor. Lung Cancer, 2012, 75, 161-166.	2.0	45
140	Strong anti-tumor effect of NVP-AUY922, a novel Hsp90 inhibitor, on non-small cell lung cancer. Lung Cancer, 2012, 76, 26-31.	2.0	42
141	Frequent methylation and oncogenic role of microRNA-34b/c in small-cell lung cancer. Lung Cancer, 2012, 76, 32-38.	2.0	102
142	Prognostic impact of cancer stem cell-related markers in non-small cell lung cancer patients treated with induction chemoradiotherapy. Lung Cancer, 2012, 77, 162-167.	2.0	86
143	Resection of the entire first rib for fibrous dysplasia using a combined posterior-transmanubrial approach. General Thoracic and Cardiovascular Surgery, 2012, 60, 584-586.	0.9	2
144	Takotsubo cardiomyopathy associated with pulmonary resections after induction chemoradiotherapy for non-small cell lung cancer. General Thoracic and Cardiovascular Surgery, 2012, 60, 599-602.	0.9	9

#	Article	IF	Citations
145	DNA methylation status of REIC/Dkk-3 gene in human malignancies. Journal of Cancer Research and Clinical Oncology, 2012, 138, 799-809.	2.5	24
146	Mechanisms and Overcome of Acquired Resistance to EGFR Tyrosine Kinase Inhibitors. Japanese Journal of Lung Cancer, 2012, 52, 131-135.	0.1	1
147	MicroRNA miR-34b/c enhances cellular radiosensitivity of malignant pleural mesothelioma cells. Anticancer Research, 2012, 32, 4871-5.	1.1	19
148	Ectopic cervical thymoma: a case report with 18F-fluorodeoxyglucose positron emission tomography findings. Acta Medica Okayama, 2012, 66, 357-61.	0.2	0
149	Molecular oncology of lung cancer. General Thoracic and Cardiovascular Surgery, 2011, 59, 527-537.	0.9	60
150	Knockdown of Oncogenic KRAS in Nonâ€“Small Cell Lung Cancers Suppresses Tumor Growth and Sensitizes Tumor Cells to Targeted Therapy. Molecular Cancer Therapeutics, 2011, 10, 336-346.	4.1	151
151	Epigenetic Silencing of MicroRNA-34b/c Plays an Important Role in the Pathogenesis of Malignant Pleural Mesothelioma. Clinical Cancer Research, 2011, 17, 4965-4974.	7.0	116
152	Aberrant methylation of p21 gene in lung cancer and malignant pleural mesothelioma. Acta Medica Okayama, 2011, 65, 179-84.	0.2	13
153	Molecular Biology of Lung Cancer. Japanese Journal of Lung Cancer, 2010, 50, 329-341.	0.1	0
154	The estrogen receptor influences microtubule-associated protein tau (MAPT) expression and the selective estrogen receptor inhibitor fulvestrant downregulates MAPT and increases the sensitivity to taxane in breast cancer cells. Breast Cancer Research, 2010, 12, R43.	5.0	56
155	Histone Deacetylase Inhibitor Romidepsin Enhances Anti-Tumor Effect of Erlotinib in Non-small Cell Lung Cancer (NSCLC) Cell Lines. Journal of Thoracic Oncology, 2009, 4, 161-166.	1.1	59
156	Alterations in Genes of the EGFR Signaling Pathway and Their Relationship to EGFR Tyrosine Kinase Inhibitor Sensitivity in Lung Cancer Cell Lines. PLoS ONE, 2009, 4, e4576.	2.5	177
157	MET gene amplification or EGFR mutation activate MET in lung cancers untreated with EGFR tyrosine kinase inhibitors. International Journal of Cancer, 2009, 124, 1778-1784.	5.1	131
158	Comprehensive analysis of EGFR signaling pathways in Japanese patients with non-small cell lung cancer. Lung Cancer, 2009, 66, 107-113.	2.0	20
159	Oncogene Mutations, Copy Number Gains and Mutant Allele Specific Imbalance (MASI) Frequently Occur Together in Tumor Cells. PLoS ONE, 2009, 4, e7464.	2.5	205
160	EGFR Mutation, But Not Sex and Smoking, Is Independently Associated with Favorable Prognosis of Gefitinib-treated Patients with Lung Adenocarcinoma. Japanese Journal of Lung Cancer, 2009, 49, 409-415.	0.1	0
161	Epidermal growth factor receptor mutation, but not sex and smoking, is independently associated with favorable prognosis of gefitinibâ€treated patients with lung adenocarcinoma. Cancer Science, 2008, 99, 303-308.	3.9	37
162	Elevated serum level of sialylated glycoprotein KL-6 predicts a poor prognosis in patients with non-small cell lung cancer treated with gefitinib. Lung Cancer, 2008, 59, 81-87.	2.0	18

#	Article	IF	Citations
163	ERCC1 protein expression predicts the response of cisplatin-based neoadjuvant chemotherapy in non-small-cell lung cancer. Lung Cancer, 2008, 59, 377-384.	2.0	78
164	Frequent p16 inactivation by homozygous deletion or methylation is associated with a poor prognosis in Japanese patients with pleural mesothelioma. Lung Cancer, 2008, 62, 120-125.	2.0	52
165	Genetic Predictors of MEK Dependence in Nonâ€“Small Cell Lung Cancer. Cancer Research, 2008, 68, 9375-9383.	0.9	235
166	PIK3CA Mutations and Copy Number Gains in Human Lung Cancers. Cancer Research, 2008, 68, 6913-6921.	0.9	399
167	Detection of EGFR Gene Mutations Using the Wash Fluid of CT-Guided Biopsy Needle in NSCLC Patients. Journal of Thoracic Oncology, 2008, 3, 472-476.	1.1	38
168	The allelic distribution of a single nucleotide polymorphism in the PDCD5 gene locus of Japanese non-small cell lung cancer patients. Molecular Medicine Reports, 2008, 1, 667-71.	2.4	7
169	Sequential Molecular Changes during Multistage Pathogenesis of Small Peripheral Adenocarcinomas of the Lung. Journal of Thoracic Oncology, 2008, 3, 340-347.	1.1	78
170	Non-BAC Component but not Epidermal Growth Factor Receptor Gene Mutation is Associated with Poor Outcomes in Small Adenocarcinoma of the Lung. Journal of Thoracic Oncology, 2008, 3, 704-710.	1.1	38
171	EGFR å‰ç•°ã• Uracil-Tegafur ã«ã‚ˆã‚‹è…ºç™Œè¡“å¾Œè£œåŠ©ç™‚æ³•ã®é–¢é€£æ€§ã«ã¤ã„ã¦ã®æœ¨Ž. Okayamadgakkaizasshi, 20		
172	The aberrant promoter methylation of BMP3b and BMP6 in malignant pleural mesotheliomas. Oncology Reports, 2008, 20, 1265-8.	2.6	20
173	The Impact of Sex and Smoking Status on the Mutational Spectrum of Epidermal Growth Factor Receptor Gene in Nonâ€“small Cell Lung Cancer. Clinical Cancer Research, 2007, 13, 5763-5768.	7.0	81
174	The Effect of Gefitinib on B-RAF Mutant Non-small Cell Lung Cancer and Transfectants. Journal of Thoracic Oncology, 2007, 2, 321-324.	1.1	5
175	Risk Factors for Recurrence and Unfavorable Prognosis in Patients with Stage I Non-small Cell Lung Cancer and a Tumor Diameter of 20 mm or Less. Journal of Thoracic Oncology, 2007, 2, 808-812.	1.1	60
176	Clinical Significance of Epidermal Growth Factor Receptor Gene Mutations on Treatment Outcome after First-line Cytotoxic Chemotherapy in Japanese Patients with Non-small Cell Lung Cancer. Journal of Thoracic Oncology, 2007, 2, 632-637.	1.1	62
177	Epidermal Growth Factor Receptor Mutation Status and Adjuvant Chemotherapy With Uracil-Tegafur for Adenocarcinoma of the Lung. Journal of Clinical Oncology, 2007, 25, 3952-3957.	1.6	42
178	EGFR mutation status in pleural fluid predicts tumor responsiveness and resistance to gefitinib. Lung Cancer, 2007, 56, 445-448.	2.0	33
179	The impact of epidermal growth factor receptor gene status on gefitinib-treated Japanese patients with non-small-cell lung cancer. International Journal of Cancer, 2007, 120, 1239-1247.	5.1	120
180	Impact ofHER2 andEGFR gene status on gefitinib-treated patients with nonsmall-cell lung cancer. International Journal of Cancer, 2007, 121, 1162-1167.	5.1	29

#	Article	IF	Citations
181	The impact and role of EGFR gene mutation on non-small cell lung cancer. Cancer Chemotherapy and Pharmacology, 2006, 58, 25-31.	2.3	7
182	Usefulness of EGFR mutation screening in pleural fluid to predict the clinical outcome of gefitinib treated patients with lung cancer. International Journal of Cancer, 2006, 119, 2353-2358.	5.1	102
183	Presence of Epidermal Growth Factor Receptor Gene T790M Mutation as a Minor Clone in Nonâ€“Small Cell Lung Cancer. Cancer Research, 2006, 66, 7854-7858.	0.9	422
184	Detection of codon 61 point mutations of the K-ras gene in lung and colorectal cancers by enriched PCR. Oncology Reports, 2003, 10, 1455-9.	2.6	42
185	A Case of Pancreatic Adenocarcinoma With Novel K -Ras Mutation and Long Term Survival. American Journal of Gastroenterology, 2002, 97, 1852-1853.	0.4	0
186	A case of pancreatic adenocarcinoma with novel K-ras mutation and long term survival. American Journal of Gastroenterology, 2002, 97, 1852-1853.	0.4	0
187	The aberrant promoter methylation of BMP3b and BMP6 in malignant pleural mesotheliomas. Oncology Reports, 1994, 20, 1265.	2.6	4